StockData

Definitive Healthcare vs Exzeo

DH and XZO side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DH and XZO compare

Exzeo is the larger company, worth 10 times as much as Definitive Healthcare ($1.4B against $140M).

Exzeo grew revenue faster over the last twelve months (6.5% versus −6.2% for Definitive Healthcare).

Exzeo keeps more of each dollar of sales as profit, with a net margin of 39.7% compared with −69.2% at Definitive Healthcare.

Exzeo scores higher on the StockData Score (13 against 5 for Definitive Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDHXZO
Size and price
Market cap$140M$1.4B
Share price$1.31$16.00
Change, 1 year−51.8%−15.3%
Change, 5 years−96.2%–
Beta (5Y)1.851.82
Employees686–
StockData Score
Total score513 (better)
Valuation score33
Growth score01 (better)
Performance score03 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–15.7×
P/S0.6× (better)6.5×
P/B–4.8×
EV/EBITDA–12.2×
P/FCF5.8× (better)17.4×
FCF yield17.3% (better)5.7%
Fair value$3.95$25.75
Margin of safety66.8% (better)37.9%
Growth
Revenue growth (TTM)−6.2%6.5% (better)
Revenue growth, 5Y average15.3%–
Net income growth (TTM)–21.4%
EPS growth (TTM)–15.9%
Profitability
Gross margin75.4% (better)62.5%
Operating margin−105%48.0% (better)
Net margin−69.2%39.7% (better)
FCF margin10.6%37.2% (better)
Return on equity–46.7%
Return on invested capital–134%
Financial health
Debt / equity–0.00
Interest coverage−22.2×–
Current ratio1.96 (better)1.53
Altman Z-score−3.2410.62 (better)
Piotroski F-score56 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.2%7.1%
Held by insiders–9.2%
Insider net buying, 12 months–$2.3M
Short interest, % of float–2.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.